Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iNK015
- Development stage
- Preclinical
- Lead developer
- Cell Inspire Biotechnology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
iNK015 is an induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell therapy developed by Cell Inspire Biotechnology. It is engineered using the company's HIP01 hypoimmune platform, which is designed to reduce host immune rejection and improve the persistence of the cells in an allogeneic setting. The therapy is further modified to express CD16 (FCGR3A) to enhance antibody-dependent cellular cytotoxicity (ADCC) when used in combination with monoclonal antibodies, and to secrete interleukin-15 (IL-15) to support the survival and proliferation of the NK cells without the need for exogenous cytokine administration. iNK015 is currently in preclinical development for the treatment of various cancers.
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on iNK015.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iNK015.